Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin added to standard care in intubated patients with COVID-19
IRCT20190417043295N2Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of ivermectin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: 30-day mortality. Started Sep 2021; status: completed.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20190417043295N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190417043295N2.